Amicus Therapeutics, Inc. (NASDAQ:FOLD) tinted gains of +1.14% (+0.16 points) to US$14.16. The volume of 6.46 Million shares climbed up over an trading activity of 3.01 Million shares. EPS ratio determined by looking at last 12 month figures is -1.87. Over the same time span, the stock marked US$17.62 as its best level and the lowest price reached was US$8.27. The corporation has a market cap of US$3.06 Billion.
Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s earnings per share has been growing at a -10.1 percent rate over the past 5 year when average revenue increase was noted as 202 percent. The return on equity ratio or ROE stands at -76 percent while most common profitability ratio return on investment (ROI) was -49.5 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 84.2 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 6 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 1.64. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Leap Therapeutics, Inc. (NASDAQ:LPTX) is worth US$42.12 Million and has recently fallen -1.04% to US$1.91. The latest exchange of 0.66 Million shares is below its average trading activity of 1.14 Million shares. The day began at US$1.89 but the price moved to US$1.89 at one point during the trading and finally capitulating to a session high of US$1.89. The stock tapped a 52-week high of US$10.25 while the mean 12-month price target for the shares is US$9.5.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.08, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 40.6%, it carries an earnings per share ratio of -1.71.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.67.